Over the past 2 decades, there has been an extraordinary progress in the regimens
developed for the treatment of human epidermal growth factor receptor 2 (HER2)-positive …

Human epidermal growth factor receptor 2 (HER2) is overexpressed and/or amplified in
approximately 20% of breast cancers, conferring an aggressive tumor behavior but also an …

Background In the single-arm, phase 2 DESTINY-Breast01 trial, trastuzumab deruxtecan
showed robust activity in patients with HER2-positive metastatic breast cancer who were …

Several new systemic therapy options have become available for patients with metastatic
breast cancer, which have led to improvements in survival. In addition to patient and clinical …

PURPOSE To update evidence-based guideline recommendations to practicing oncologists
and others on systemic therapy for patients with human epidermal growth factor receptor 2 …

Amplification and/or overexpression of ERBB2, the gene encoding HER2, can be found in
15–20% of invasive breast cancers and is associated with an aggressive phenotype and …

HER2 status in breast cancer is assessed to select patients eligible for targeted therapy with
anti-HER2 therapies. According to the American Society of Clinical Oncology (ASCO) and …

The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Breast Cancer
address all aspects of management for breast cancer. The treatment landscape of metastatic …

Simple Summary The progress of next-generation sequencing technologies has raised
huge expectations for precision-medicine therapy approaches in breast cancer and triple …

Background Anti-HER2 therapies are associated with a risk of increased cardiac toxicity,
particularly when part of anthracycline-containing regimens. We report cardiac safety of …